Dr Jeremy S. Abramson evaluates data from the primary analysis of the PILOT study and a meta-analysis of CAR-T therapy versus standard-of-care for second-line treatment of refractory or relapsed LBCL.
Learn more about our family of publications.
View Our Publications
Supported through funding by